InvestorsHub Logo

polarbear77

12/30/19 12:29 PM

#227329 RE: frrol #227325

That’s your enervated opinion based upon your own personal view of one graph, and your opinion happens to run contrary to the leading Rett Syndrome researcher’s statement and commentary on the subject.

The same RS researcher who is our CMO and is in possession of all of the data regarding the trial and its participants and their open label extension data.

Personally I’ll stick with Dr Kaufmann.


WolfofMia

12/30/19 2:55 PM

#227359 RE: frrol #227325

I agree we need more data, at least the trial met its endpoints for safety.